Nisia Gomes

INITIAL RESULTS AND LONG-TERM FOLLOW-UP OF PERCUTANEOUS MITRAL VALVULOPLASTY IN PATIENTS WITH PULMONARY HYPERTENSION

Background: Percutaneous balloon mitral valvuloplasty (PMV) is an attractive therapeutic approach in patients with mitral stenosis. The aim of this study was to assess the immediate and long-term clinical, echocardiographic and haemodynamic outcomes of PMV in patients with severe pulmonary

INDEPENDENT PRE PROCEDURAL ECHOCARDIOGRAPHIC PREDICTORS OF MITRAL VALVE RESTENOSIS AFTER PERCUTANEOUS MITRAL BALLOON VALVULOPLASTY IN A LARGE CONSECUTIVE COHORT FOLLOWED UP TO TWO DECADES

Background: Percutaneous Mitral Balloon Valvuloplasty (PMBV), has been the preferred treatment for mitral valve stenosis, particularly when secondary to rheumatic heart disease. However, its recurrence is found to happen, due to unclear factors, in a significant number of patients submitted to this

PREDICTORS OF IMMEDIATE AND VERY LATE EVENTS AFTER PERCUTANEOUS MITRAL VALVULOPLASTY

Background: Data on long-term outcomes of percutaneous balloon mitral valvuloplasty (PMV) are still scarce. We sought to access immediate and very long late events after PMV. Methods: We prospectively enrolled 1,582 patients who underwent PMV from 1987 to 2011 at a single-center. The primary

TCT-44 Independent Mitral Valve Restenosis Predictors After Percutaneous Mitral Balloon Valvuloplasty In A Large, Consecutive Cohort Followed For More Than Two Decades

Percutaneous Mitral Balloon Valvuloplasty (PMBV), whenever technically feasible, is the preferred treatment option for mitral stenosis, particularly those secondary to rheumatic heart disease. Nevertheless, mitral valvular restenosis might develop in a significant number of patients submitted to

TCT-628 Very Long-Term (Up To 23 Years) Follow-Up After Successful Mitral Balloon Valvuloplasty In A Large Series Of Patients With Rheumatic Mitral Stenosis.

Introduction: Although there has been a steady decline in the incidence of rheumatic heart disease, rheumatic mitral stenosis still causes significant morbi-mortality worldwide. Percutaneous mitral balloon valvuloplasty (PMBV) remains as the preferred treatment option for patients with suitable anatomy and severe symptomatic rheumatic mitral stenosis. Hypothesis: We sought to assess the very long-term outcomes after successful PMBV. Methods: This is a single center analysis of all consecutive patients who underwent successful PBMV (post-procedural valve area ≥ 1.5 cm 2 and regurgitation moderate or less, without in-hospital major adverse cardiac and cerebrovascular events) between 1988 and 2011. The primary endpoint was to determine the incidence of major adverse cardiac events (MACE), including global death and need for mitral surgery or repeat PMBV up to 23 year after the procedure. Results: Among all 1577 patients, the success rate was achieved in 91.3% (1140 patients). The predictors of success were NYHA functional class III-IV (hazard ratio [HR]: 1.73, 95% CI: 1.15-2.60, p=0.008) and Wilkins-score Conclusions: Up to 23 years after successful PMBV, a sizeable proportion of patients still exhibit sustained results after PMBV.